Live feed08:05:00·47dNEWSReleasevia QuantisnowAptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose SelectionByQuantisnow·Wall Street's wire, on your screen.APVO· Aptevo Therapeutics Inc.Health Care
